MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge(Caris Life Sciences (United States)), Antonio Llombart‐Cussac(MedSIR (Spain)), Eva‐Maria Grischke(Universitair Ziekenhuis Leuven), Peter A. Kaufman(University of Vermont), Susana Barriga(Universitair Ziekenhuis Leuven), Olga Burdaeva(Universitair Ziekenhuis Leuven), Joohyuk Sohn(Yonsei University), Nawel Bourayou(Universitair Ziekenhuis Leuven), Martin Frenzel(Universitair Ziekenhuis Leuven), Xavier Pivot(Levi Strauss (United States)), Norikazu Masuda(Kyoto University), Meena Okera(Universitair Ziekenhuis Leuven), Ian C. P. Smith(Royal Marsden Hospital), Masakazu Toi(Mukogawa Women's University), Kenichi Inoue(Universitair Ziekenhuis Leuven), Yong Lin(Fujian Medical University), Han Koh(Universitair Ziekenhuis Leuven), Patrick Neven(KU Leuven)
Cited by 1,654
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k